Name: Latest research reports of Zydus Lifesciences Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Karvy

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer

930.0000 5.25 (0.57%)

NSE May 30, 2025 15:31 PM

29.77% Fall from 52W High

Volume: 1.9M

Zydus Lifesciences Ltd.

08 Feb 2020

930.00

0.57%

Cadila Healthcare Ltd: Pharmaceuticals

Buy: Zydus Lifesciences Ltd.

Target

Karvy

We upgrade our Revenues by 1.8%/2.8% in FY20E/FY21E due to upgrade in USand EM business. We downgrade our EBITDAM by 40bps to 18.9% for FY20Ewhile we maintain our EBITDAM for FY21E.

Zydus Lifesciences Ltd. is trading above its 100 day SMA of 915.2